Lupus Biobank for Newly Diagnosed Patients
Part of Immune system & allergy, Skin clinical trials.
This study is building a national biobank (a storage of blood and health information) to learn more about lupus in people who were recently diagnosed (within the last 2 years). It's for patients whose lupus is not causing serious damage to major organs, so that researchers can study how the disease behaves early on.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with lupus within the last 2 years.
- Your lupus should not be affecting major organs like your kidneys, brain, heart, or lungs in a serious way.
- You cannot have taken steroids or certain biologic medications (like Benlysta) in the last 3 months.
- You cannot have other autoimmune diseases (like rheumatoid arthritis) or conditions that require steroids (like asthma).
- You must not be pregnant or planning pregnancy, and you must be able to stay in long-term follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This study is looking for biomarkers (clues in your blood, urine, or tissue) that can help predict how well lupus nephritis (kidney inflammation caused by lupus) responds to treatment. It focuses on people who have active kidney disease and are either starting treatment or have been on a stable treatment for at least a month.
This study follows people newly diagnosed with lupus (SLE) to understand how the disease develops over time. It looks at what happens before treatment starts or soon after diagnosis, and aims to improve care for lupus patients across Europe.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.